ZVRA
ZVRA
US4884452065
Zevra Therapeutics, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 100/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±61.2% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Largely moves in line with the broader market.

Beta (Market Relation)
0.98x
Defensive
Volatility (5Y p.a.)
61.2% p.a.
5-Year Horizon
Max Drawdown (5Y)
-60.8%
5-Year Horizon
Sharpe Ratio
0.03
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +3.4%
3 Years 61.1% -43.5% 0.51 +33.5%
5 Years 61.2% -60.8% 0.03 +4.6%
10 Years 82.7% -97.8% -0.24 -16.9%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (61.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -97.8% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
8 ISS Score: 8 / 10
Audit Risk
8 ISS Score: 8 / 10
Board Risk
7 ISS Score: 7 / 10
Short Ratio
6.77
ende